Add to ORKGCore binding factor acute myelogenous leukemia (CBF AML) constitutes 15% of adult AML and carries an overall good prognosis. CBF AML encodes two recurrent cytogentic abnormalities referred to as t(8;21) and inv (16). The two CBF AML entities are usually grouped together but there is a considerable clinical, pathologic and molecular heterogeneity within this group of diseases. Recent and ongoing studies are addressing the molecular heterogeneity, minimal residual disease and targeted therapies to improve the outcome of CBF AML. In this article, we present a comprehensive review about CBF AML with emphasis on molecular heterogeneity and new therapeutic options. Am. J. Hematol. 89:1121-1131, 2014. (c) 2014 Wiley Periodicals, Inc
The core binding factor (CBF) transcription factor complex is involved in the regulation of a number...
Background: Although the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is bett...
Approximately 40% of patients affected by core binding factor (CBF) acute myeloid leukemia (AML) ult...
Core binding factor acute myelogenous leukemia (CBF AML) constitutes 15% of adult AML and carries an...
Abstract Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of ...
Core binding factor (CBF) leukemias, characterized by either inv(16)/t(16;16) or t(8;21), constitute...
Core binding factor acute myeloid leukemia (CBF-AML) is a favorable acute myeloid leukemia (AML) sub...
KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identificatio...
Aim. To address the heterogeneity of CBF AML patients- t(8;21)(q22;q22)/RUNX1-RUNX1T1 and inv(16)(p1...
International audienceCore-binding factor acute myeloid leukemia is a favorable acute myeloid leukem...
International audienceAlthough core-binding factor-acute myeloid leukemia (CBF-AML) (t[8;21] or inv[...
BackgroundAlthough the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better...
International audienceAcute myeloid leukemia (AML) with t(8;21) and inv(16), together referred as co...
The core binding factor (CBF) transcription factor complex is involved in the regulation of a number...
Background: Although the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is bett...
Approximately 40% of patients affected by core binding factor (CBF) acute myeloid leukemia (AML) ult...
Core binding factor acute myelogenous leukemia (CBF AML) constitutes 15% of adult AML and carries an...
Abstract Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of ...
Core binding factor (CBF) leukemias, characterized by either inv(16)/t(16;16) or t(8;21), constitute...
Core binding factor acute myeloid leukemia (CBF-AML) is a favorable acute myeloid leukemia (AML) sub...
KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identificatio...
Aim. To address the heterogeneity of CBF AML patients- t(8;21)(q22;q22)/RUNX1-RUNX1T1 and inv(16)(p1...
International audienceCore-binding factor acute myeloid leukemia is a favorable acute myeloid leukem...
International audienceAlthough core-binding factor-acute myeloid leukemia (CBF-AML) (t[8;21] or inv[...
BackgroundAlthough the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better...
International audienceAcute myeloid leukemia (AML) with t(8;21) and inv(16), together referred as co...
The core binding factor (CBF) transcription factor complex is involved in the regulation of a number...
Background: Although the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is bett...
Approximately 40% of patients affected by core binding factor (CBF) acute myeloid leukemia (AML) ult...